3205.TWO Sagittarius Life Science
- Market cap
- TWD 2.89B
- P/E
- -
- P/B
- 2.97x
- ROE
- 0.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 3205.TWO undervalued?
Graham numberThe Graham number of Sagittarius Life Science cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sagittarius Life Science fundamental analysis
No fundamental analysis for Sagittarius Life Science yet.
Sagittarius Life Science stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology, as well as meat products. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.
Full company profileSagittarius Life Science financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sagittarius Life Science annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.38B | 463M | 411M | 439M | 558M | 588M | 529M | 440M | 468M | 346M | 670M |
| Gross Profit | 576M | 119M | 63.1M | 69.1M | 110M | 101M | 82.6M | 71.5M | 81.1M | 57.7M | 44.9M |
| Operating Income | 358M | -82.3M | -115M | -105M | -73.7M | -87.1M | -76.3M | -56.7M | -61.6M | -58.5M | -9.52M |
| EBITDA | - | -110M | -102M | -83.7M | -47.6M | -62.9M | -55.4M | -41.7M | -34.7M | -39.5M | 9.02M |
| Net Income | 268M | -114M | -91.8M | -120M | -74.1M | -86.4M | -74.2M | -55.0M | -48.5M | -49.6M | 3.35M |
| EPS | - | -3.48 | -2.80 | -3.65 | -2.27 | -2.66 | -2.28 | -1.69 | -1.49 | -0.73 | 0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 1.41B | 1.06B | 894M | 812M | 741M | 676M | 579M | 665M | 520M | 1.07B | 1.14B |
| Total Liabilities | 201M | 97.2M | 96.4M | 137M | 152M | 144M | 124M | 138M | 100M | 26.9M | 134M |
| Shareholders' Equity | 1.21B | 965M | 797M | 674M | 586M | 517M | 442M | 515M | 408M | 1.04B | 1.00B |
| Cash & Short-term Investments | 869M | 833M | 648M | 523M | 400M | 359M | 270M | 215M | 83.8M | 152M | 154M |
| Total Debt | - | - | - | - | 37.6M | 24.0M | 11.4M | 13.3M | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 360M | -23.3M | -57.9M | -105M | -62.2M | -29.2M | -52.9M | -69.4M | -44.5M | -36.0M | -378M |
| Capital Expenditure | 19.8M | 2.91M | 101K | 14.7M | 11.2M | 8.43M | 1.09M | 2.01M | 3.80M | 404K | 0.00 |
| Free Cash Flow | - | -26.2M | -58.3M | -119M | -73.4M | -37.6M | -54.0M | -71.4M | -48.3M | -36.5M | -480M |
| Ratios | |||||||||||
| ROE | 22.1% | -11.8% | -11.5% | -17.7% | -12.6% | -16.7% | -16.8% | -10.7% | -11.9% | -4.8% | 0.3% |
| ROA | 19.0% | -10.7% | -10.3% | -14.7% | -10.0% | -12.8% | -12.8% | -8.3% | -9.3% | -4.6% | 0.3% |
| Net Profit Margin | 19.4% | -24.7% | -22.3% | -27.2% | -13.3% | -14.7% | -14.0% | -12.5% | -10.4% | -14.3% | 0.5% |
| Debt to Equity | - | - | - | - | 0.06x | 0.05x | 0.03x | 0.03x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sagittarius Life Science dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Aug 31, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | TWD 52.6M | 1.61 | - |
| 2017 | TWD 131M | 4.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1048.659:1000 on Aug 17, 2016.
Who owns Sagittarius Life Science
- Insiders 70.18%
- Institutions 0.00%
- Public & others 29.82%
- Shares outstanding 67.5M
- Free float 17.5M
Sagittarius Life Science company profile
- Company name
- Sagittarius Life Science
- Ticker
- 3205.TWO
- ISIN
- TW0003205001
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No.3, Yuanqu Street, Taipei, Taiwan
- Phone
- 886 2 2655 7166
- Website
- naturalbiokey.com
About Sagittarius Life Science
Sagittarius Life Science Corp engages in the research, development, and sale of Chinese and western medicines, and health food products in Taiwan and Asia. It also offers organic food, daily necessities, and pet food; and engages in the research and development of biotechnology, as well as meat products. Sagittarius Life Science Corp was founded in 1998 and is based in Taipei, Taiwan.
Sagittarius Life Science management
1- Di-Miao WuAccounting Supervisor